Drug
Casopitant clinical trials
Also written GW679769.
- studies test it
- 28
- open now
- 0
- in phase 3
- 5
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
- GW679769
- 13
Combined with it in one product
Studies by the year they started
28 studies that test it; most in 2006 (14)
| Year | Studies |
|---|---|
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 4 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 12
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 0
Often tested with
Tested in the same studies.
Dexamethasone (3) · Ondansetron (2) · Rifampin (1) · Ketoconazole (1) · Warfarin (1) · Docetaxel (1) · Dolasetron (1) · Granisetron (1)
Studies
Open first, then newest update. How each study uses casopitant is read from its arms, and is right about nine times in ten.
Testing it · 28
- A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.CompletedPhase 3GlaxoSmithKlineNCT00601172Written as Casopitant
- Cyclophosphamide Drug Interaction Study In Cancer PatientsTerminatedPhase 1GlaxoSmithKlineNCT00334646Written as Oral GW679769
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT00437229Written as Casopitant (GW679769) Oral Tablets
- Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic ImpairmentCompletedPhase 1GlaxoSmithKlineNCT00359177Written as GW679769
- A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).CompletedPhase 1GlaxoSmithKlineNCT00405080Written as GW679769 (Casopitant) oral tablets
- Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]CompletedPhase 1GlaxoSmithKlineNCT00404378Written as casopitant 100 mg
- A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic ChemotherapyCompletedPhase 3GlaxoSmithKlineNCT00431236Written as Oral Casopitant (GW679769)
- A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human VolunteersCompletedPhase 1GlaxoSmithKlineNCT00404274Written as Casopitant (GW679769) oral tablets
- A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary InsomniaCompletedPhase 2GlaxoSmithKlineNCT00650871Written as GW679769
- Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal ImpairmentCompletedPhase 1GlaxoSmithKlineNCT00358813Written as Casopitant
- The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With CancerCompletedPhase 1GlaxoSmithKlineNCT00440128Written as Casopitant/Docetaxel
- The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in SubjectsCompletedPhase 1GlaxoSmithKlineNCT00511823Written as casopitant
- A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT00460707Written as Casopitant 150 mg
- Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In WomenCompletedPhase 3GlaxoSmithKlineNCT00334152Written as casopitant
- An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional DyspepsiaCompletedPhase 2GlaxoSmithKlineNCT00358410Written as GW679769 oral tablets
- Post-Operative Nausea And Vomiting Study In Female PatientsCompletedPhase 2GlaxoSmithKlineNCT00274690Written as GW679769
- A Study Of GW679769 Compared To Placebo In Women With Overactive BladderCompletedPhase 2GlaxoSmithKlineNCT00321477Written as GW679769 oral tablets
- Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)CompletedPhase 2GlaxoSmithKlineNCT00413023Written as GW679769
- Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In WomenCompletedPhase 3GlaxoSmithKlineNCT00326248Written as GW679769 (casopitant)
- Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury PatientsTerminatedPhase 2GlaxoSmithKlineNCT00332319Written as GW679769
See all 28 studies that test casopitant →
As the comparator · 1 — what is tested is compared with casopitant
Codes
What other systems call casopitant · ClinicalTrials.gg INT005328
- MeSH (NLM) C531951casopitantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3B03KPM27LCASOPITANTConfirmed FDA, NLM, Wikidata
- Wikidata Q5049003casopitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71635CasopitantOne source FDA
- DrugBank DB06634One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531951 | casopitant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3B03KPM27L | CASOPITANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5049003 | casopitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71635 | Casopitant | One source FDA |
| DrugBank | DB06634 | — | One source Wikidata |
Also registered as casopitant mesylate (UNII 7VSV9BL497).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.